<- Go Home
Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Market Cap
$52.8M
Volume
948.9K
Cash and Equivalents
$81.4K
EBITDA
-$6.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$127.8K
Profit Margin
78.82%
52 Week High
$4.36
52 Week Low
$0.25
Dividend
N/A
Price / Book Value
10.65
Price / Earnings
-6.14
Price / Tangible Book Value
11.21
Enterprise Value
$48.2M
Enterprise Value / EBITDA
-7.43
Operating Income
-$6.5M
Return on Equity
135.57%
Return on Assets
-83.89
Cash and Short Term Investments
$4.6M
Debt
N/A
Equity
$5.0M
Revenue
$162.1K
Unlevered FCF
-$1.8M
Sector
Health Care Equipment and Supplies
Category
N/A